Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. - Wikidata - wikimedia - TriplyDB

Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma.

Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma.

http://www.wikidata.org/entity/Q33730122

about

Vascular Wall-Resident Multipotent Stem Cells of Mesenchymal Nature within the Process of Vascular Remodeling: Cellular Basis, Clinical Relevance, and Implications for Stem Cell Therapy Tumor endothelial cells Combined toll-like receptor 3/7/9 deficiency on host cells results in T-cell-dependent control of tumour growth Adrenomedullin as a therapeutic target in angiogenesis.Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves the antiangiogenic efficacy for advanced stage mouse corneal neovascularization.The antiangiogenic 16K prolactin impairs functional tumor neovascularization by inhibiting vessel maturation.Desmin expression in colorectal cancer stroma correlates with advanced stage disease and marks angiogenic microvessels.Gene-expression profiling of microdissected breast cancer microvasculature identifies distinct tumor vascular subtypes Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth.Netrin-4 delays colorectal cancer carcinomatosis by inhibiting tumor angiogenesis.A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor.Innovations in studying in vivo cell behavior and pharmacology in complex tissues--microvascular endothelial cells in the spotlight.Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination.Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial.Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic dissemination.Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy Chronic inflammation and immunologic-based constraints in malignant disease.Influence of morphine on pericyte-endothelial interaction: implications for antiangiogenic therapy Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice Hypoxia differentially regulates arterial and venous smooth muscle cell proliferation via PDGFR-β and VEGFR-2 expression.Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers.Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model.VEGF dose regulates vascular stabilization through Semaphorin3A and the Neuropilin-1+ monocyte/TGF-β1 paracrine axis Small GTPase R-Ras regulates integrity and functionality of tumor blood vessels A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells Requirement of novel amino acid fragments of orphan nuclear receptor TR3/Nur77 for its functions in angiogenesis Safety and efficacy of the multitargeted receptor kinase inhibitor pazopanib in the treatment of corneal neovascularization.Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination Pericytes on the tumor vasculature: jekyll or hyde?Differential function and regulation of orphan nuclear receptor TR3 isoforms in endothelial cells.Drug resistance and the role of combination chemotherapy in improving patient outcomes.Remodeling of tumor stroma and response to therapy.Markers of fibroblast-rich tumor stroma and perivascular cells in serous ovarian cancer: Inter- and intra-patient heterogeneity and impact on survival Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?DLK1: a novel target for immunotherapeutic remodeling of the tumor blood vasculature.Controlling escape from angiogenesis inhibitors.Thrombospondin-2 overexpression in the skin of transgenic mice reduces the susceptibility to chemically induced multistep skin carcinogenesis Tumor vasculature as target for therapeutic intervention.Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: one step forward for overcoming anti-angiogenic drug resistance?

P2860

Q26765919-CB693E61-A97D-4AC7-83AC-3E1C8514BA4D Q26995733-B57AB632-ED28-45D1-A3AD-0553CBF31866 Q30842176-DCFC64CF-B0FE-49F8-9E79-AB9AB0FC8FD8 Q33693793-3A0A348D-D237-4203-AE66-06E3C7781126 Q33770680-FA20454C-E136-4EED-8D17-B2950A47884D Q33901062-91BF97EC-F526-499F-BB0D-1AA6FD0B3467 Q34075597-41727231-0DBF-45F3-B9BA-CAF941FCE6BD Q34091609-E2073195-EE73-4117-A174-86D42461977F Q34385677-5AEA25BE-7792-4219-BBF1-7C40801DEA5E Q34643612-4F8D7D97-85FD-4A15-BC05-F5EF176FC7D0 Q34805721-6D6B7833-509E-4F09-8C73-1988771D26F0 Q34973743-89FB3EC7-6984-4327-AB45-9E010965D7E6 Q35000486-A7305F0A-A7FB-4EA1-8665-3C8E1A534AC4 Q35033957-7673CA2C-B549-45E1-833A-6DA322F6B19A Q35475535-3A38074A-895C-4CDA-A43C-5087EB0A5D15 Q35544528-F94A593F-EF47-4D4E-952C-3D679EE59894 Q35552373-1A11AE22-F9FA-426F-97A1-59E356AC36A7 Q35575974-997969CA-37FA-40A3-85CF-FA0C595D55C1 Q35725355-ED041A1D-697B-41E5-8BFC-FE52933DF882 Q35740182-3BE88224-7D0D-47AC-AD32-E4E90F54E00F Q35850042-80EF70B5-1427-428C-A1C1-54FA9F6EFCCE Q35915719-10D6C66C-282B-4039-BDD4-1A3BF6A4A58F Q35923178-14CDED18-1127-4162-8DA7-B2100DD57C3B Q36159478-5DACAAFD-D19E-4B03-84A0-7F28E811FDE3 Q36174151-6957624A-D432-4DE1-B16A-2677C2DB53C8 Q36188833-36FE5305-4599-442E-9749-1F57795741F6 Q36414440-8916C7BC-E5F7-4950-ABDF-750146D22875 Q36571709-80C4FC9E-4294-422E-B2FC-50DBDD29A575 Q36694132-E6A8240F-E5AA-4E5C-82FF-552E829BBC69 Q36695062-B1AE8D09-F795-49C2-A1C4-70E4F80CB94D Q36814082-D98B2B28-92B1-4C0A-AF7A-A597FBB93DF5 Q36999509-8F3AD776-F127-4F7A-874A-465C21105DB4 Q37016995-BC387EC1-5DFC-43F5-B9C9-EE9B73555591 Q37109818-7820E6AD-0D6F-4ED6-9F1C-404343DE5624 Q37236229-E5727021-BAEC-4E9D-B91C-4C85DE3D1DA3 Q37254877-C9A93E41-1CF0-4ABB-92E1-8EE69CCDF5AF Q37672654-5910459D-7233-4605-B1EB-93FD6A08A84A Q37684615-08C98866-EB75-49BB-833D-F03FFBB21287 Q37800110-06CC59C2-A799-4565-A038-C4ECEC39A2F0 Q37846342-E9E2FD07-3710-4C82-956B-2FEABEC38D91

P2860

Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma.

http://www.wikidata.org/entity/Q33730122

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Resistance to antiangiogenic t ...... uration in malignant melanoma.

@ast

Resistance to antiangiogenic t ...... uration in malignant melanoma.

@en

type

label

Resistance to antiangiogenic t ...... uration in malignant melanoma.

@ast

Resistance to antiangiogenic t ...... uration in malignant melanoma.

@en

prefLabel

Resistance to antiangiogenic t ...... uration in malignant melanoma.

@ast

Resistance to antiangiogenic t ...... uration in malignant melanoma.

@en

P1433

Q33730122-27668B5C-02E7-48E5-BC40-C25A6469B1B6

P1476

Q33730122-3978076B-BFE6-4C67-8574-63D33D0A69D2

P2093

Q33730122-1978899C-81DD-446C-BD5B-5BA9111C63A0

Q33730122-24BCB14B-11A5-4F3A-8B4B-4B4E79888A16

Q33730122-2FA90912-B543-47F8-B194-7383AE590FE9

Q33730122-45932894-38DE-4658-8475-FDBAA172E7D3

Q33730122-8B84A8E5-30E3-4DB9-A468-1AE6F7D562C5

Q33730122-AA47431D-6A6A-4CEE-B628-5CFADF62C5BA

Q33730122-ACB53C7B-9DB6-41F5-9B58-B1E3BEECDA03

Q33730122-EFBB8556-8FF8-4756-88C9-329C99353D7E

Q33730122-F1EC9A4D-B936-42C9-8E2D-8DD99FA371DA

P2860

Q33730122-0619B062-EEA3-472F-A160-A4B9AE123F02

Q33730122-097920BB-7762-48BA-B491-752450DD2043

Q33730122-0DDB1373-586A-4150-9A62-B4420B22E58A

Q33730122-0E234C79-8143-4EC2-9040-A8BD75EBF99A

Q33730122-1018C83E-55A9-4E1F-A318-C2F3B59C2722

Q33730122-124E0062-E317-4BD5-A971-930EEC62A5F3

Q33730122-29AFBA29-B59A-49DA-B8EF-897D27235998

Q33730122-29F6DAD4-A11B-451D-9455-FDDA78FDF93B

Q33730122-2BD36471-7820-4DD0-9DB3-27E717EEBE76

Q33730122-3367A9F5-706C-43ED-8215-56B72BF76269

P304

Q33730122-C176BB60-3AF5-46F7-BC26-51BAAC651FE5

P31

Q33730122-7FD63E46-D7E5-475E-9CEE-891C5B4A2AF2

P356

Q33730122-B1CE6BA6-B93A-4047-8619-8717E43B5B51

P407

Q33730122-A6118B2C-4DBE-4129-8E84-F67482735F6A

P433

Q33730122-D00AD2A4-2108-48D5-8966-0FA35F192D97

P478

Q33730122-47C7791B-7C87-424B-B823-EB878848B058

P50

Q33730122-84BAD120-3A38-4064-86E6-1242B9E4AAFD

Q33730122-F0FF2446-3F1B-49FD-B7DB-AD1FCA6A8826

P577

Q33730122-8666AD03-791A-4ABA-BE44-D5918E6675D4

P5875

Q33730122-6AE58089-B199-4473-9338-AFB5709E15B2

P698

Q33730122-04C4C1ED-50B3-41FB-9098-9187EB9CAB73

P932

Q33730122-F1F8E792-2921-404B-8826-588E826850F9

P356

P1433

Journal of Experimental Medicine

P1476

Resistance to antiangiogenic t ...... uration in malignant melanoma.

@en

P2093

Helmut G Augustin

http://www.w3.org/2001/XMLSchema#string

Inka Scheffrahn

http://www.w3.org/2001/XMLSchema#string

Iris Helfrich

http://www.w3.org/2001/XMLSchema#string

Joachim Weis

http://www.w3.org/2001/XMLSchema#string

Mark Middleton

http://www.w3.org/2001/XMLSchema#string

Masahi Kato

http://www.w3.org/2001/XMLSchema#string

Sönke Bartling

http://www.w3.org/2001/XMLSchema#string

Süleyman Ergün

http://www.w3.org/2001/XMLSchema#string

Verena von Felbert

http://www.w3.org/2001/XMLSchema#string

P2860

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Sorafenib in advanced clear-cell renal-cell carcinoma

Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration

Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies

P304

491-503

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.20091846

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

207

http://www.w3.org/2001/XMLSchema#string

P50

Dirk Schadendorf

Sönke Bartling

P577

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41656753

http://www.w3.org/2001/XMLSchema#string

P698

20194633

http://www.w3.org/2001/XMLSchema#string

P932

2839146

http://www.w3.org/2001/XMLSchema#string